Randomized study to compare olmesartan + azelnidipine versus valsartan + amlodipine to maximize blood pressure control and organ protection

Randomized study to compare olmesartan + azelnidipine versus valsartan + amlodipine to maximize blood pressure control and organ protection - The combination of olmesartan and azelnidipine in high-risk hypertensive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006605

Enrollment

Registered

2011-10-24

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

olmesartan + azelnidipine valsartan + amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Essential hypertensive patients without receiving ARB administration and baseline BP is over 140/90 mmHg at least two BP measurements within 8 weeks.

Exclusion criteria

Exclusion criteria: Patients were excluded from the study if there was any evidence of secondary hypertension, renal failure (serum creatinine&#8805;2.0mg/dl), severe liver dysfunction, symptomatic heart failure, and past history of cerebral infarction.

Design outcomes

Primary

Measure	Time frame
The efficacy of clinic and home blood pressure control	—

Secondary

Measure	Time frame
CAVI(Cardio-Ankle Vascular Index)	—

Countries

Japan

Contacts

Public ContactYamada Hiroyuki

Kyoto Prefectural University School of Medicine Department of Cardiovascular Medicine

hiyamada@koto.kpu-m.ac.jp075-251-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026